loading
Apellis Pharmaceuticals Inc stock is traded at $19.59, with a volume of 2.93M. It is down -2.49% in the last 24 hours and up +6.53% over the past month. Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$20.09
Open:
$20.12
24h Volume:
2.93M
Relative Volume:
1.23
Market Cap:
$2.46B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-9.6502
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
+0.62%
1M Performance:
+6.53%
6M Performance:
-34.70%
1Y Performance:
-49.61%
1-Day Range:
Value
$19.33
$20.30
1-Week Range:
Value
$19.09
$20.32
52-Week Range:
Value
$16.10
$41.94

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Name
Name
Apellis Pharmaceuticals Inc
Name
Phone
617-977-5700
Name
Address
100 FIFTH AVENUE, WALTHAM, KY
Name
Employee
710
Name
Twitter
@ApellisPharma
Name
Next Earnings Date
2024-12-05
Name
Latest SEC Filings
Name
APLS's Discussions on Twitter

Compare APLS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
APLS
Apellis Pharmaceuticals Inc
19.59 2.52B 715.22M -250.10M -205.58M -2.03
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Date Action Analyst Rating Change
May-09-25 Downgrade BofA Securities Buy → Neutral
May-09-25 Downgrade Raymond James Strong Buy → Outperform
Apr-29-25 Initiated Cantor Fitzgerald Overweight
Dec-17-24 Downgrade Goldman Buy → Neutral
Nov-21-24 Initiated Morgan Stanley Equal-Weight
Oct-25-24 Initiated RBC Capital Mkts Sector Perform
Oct-16-24 Initiated Scotiabank Sector Outperform
Oct-16-24 Initiated William Blair Outperform
May-31-24 Initiated Piper Sandler Neutral
Feb-05-24 Upgrade Jefferies Hold → Buy
Dec-14-23 Downgrade Wells Fargo Overweight → Equal Weight
Nov-09-23 Initiated Goldman Buy
Nov-02-23 Initiated Mizuho Neutral
Oct-06-23 Upgrade JP Morgan Neutral → Overweight
Sep-15-23 Upgrade Wells Fargo Equal Weight → Overweight
Aug-29-23 Reiterated Citigroup Buy
Aug-03-23 Downgrade JP Morgan Overweight → Neutral
Aug-01-23 Downgrade BofA Securities Buy → Neutral
Jan-03-23 Downgrade Wells Fargo Overweight → Equal Weight
Nov-10-22 Downgrade Jefferies Buy → Hold
Jul-19-22 Initiated H.C. Wainwright Buy
Jun-17-22 Resumed Stifel Buy
Apr-14-22 Downgrade ROTH Capital Neutral → Sell
Dec-08-21 Initiated Wells Fargo Overweight
Nov-29-21 Downgrade ROTH Capital Buy → Neutral
Sep-10-21 Reiterated BMO Capital Markets Outperform
Sep-10-21 Reiterated Credit Suisse Neutral
Sep-10-21 Reiterated Needham Buy
Sep-10-21 Reiterated Oppenheimer Outperform
Sep-10-21 Downgrade Wedbush Outperform → Neutral
Aug-19-21 Initiated Jefferies Buy
Aug-19-21 Upgrade Wedbush Neutral → Outperform
May-21-21 Initiated UBS Buy
Apr-16-21 Initiated Goldman Buy
Nov-19-20 Initiated Needham Buy
Sep-01-20 Initiated Stifel Buy
Jul-20-20 Initiated ROTH Capital Buy
Jun-17-20 Initiated BTIG Research Neutral
Apr-01-20 Initiated Raymond James Strong Buy
Mar-31-20 Initiated BMO Capital Markets Outperform
Mar-11-20 Upgrade Wedbush Underperform → Neutral
Jan-07-20 Initiated SVB Leerink Mkt Perform
Dec-19-19 Initiated BofA/Merrill Buy
Nov-22-19 Initiated Wedbush Underperform
Nov-05-19 Initiated Credit Suisse Neutral
Aug-01-19 Reiterated Cantor Fitzgerald Overweight
Jul-12-19 Upgrade JP Morgan Neutral → Overweight
Mar-29-19 Initiated Robert W. Baird Outperform
Jan-23-19 Downgrade JP Morgan Overweight → Neutral
Jul-30-18 Upgrade B. Riley FBR Neutral → Buy
May-24-18 Initiated Cantor Fitzgerald Overweight
Apr-12-18 Downgrade B. Riley FBR, Inc. Buy → Neutral
Feb-08-18 Initiated B. Riley FBR, Inc. Buy
View All

Apellis Pharmaceuticals Inc Stock (APLS) Latest News

pulisher
Jul 25, 2025

Is Apellis Pharmaceuticals Inc. a good long term investmentOver 200% growth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Apellis Pharmaceuticals Inc. stockSky-high return potential - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025 - GuruFocus

Jul 24, 2025
pulisher
Jul 24, 2025

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results - The Manila Times

Jul 24, 2025
pulisher
Jul 24, 2025

Fierce Biotech Layoff Tracker 2025: Rocket ejects 30% of staffers; Flagship's Tessera and Generate Bio trim teams - Fierce Biotech

Jul 24, 2025
pulisher
Jul 23, 2025

Complement 3 Glomerulopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | NovelMed Therapeutics, Apellis Pharma, Novartis, Amyndas Pharma - Barchart.com

Jul 23, 2025
pulisher
Jul 23, 2025

Apellis Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding trading profits - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Apellis Pharmaceuticals Inc. stock priceExceptional market performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Intermediate Age-Related Macular Degeneration Market Research 2025-2035 Featuring Novartis, Allegro Ophthalmics, and Apellis PharmaceuticalsResearchAndMarkets.com - FinancialContent

Jul 21, 2025
pulisher
Jul 18, 2025

Baird Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Raises Target Price to $50 - 富途牛牛

Jul 18, 2025
pulisher
Jul 18, 2025

Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) - Benzinga

Jul 18, 2025
pulisher
Jul 16, 2025

APLS Stock Update: B of A Securities Raises Price Target | APLS - GuruFocus

Jul 16, 2025
pulisher
Jul 16, 2025

Apellis price target raised to $24 from $23 at BofA - TipRanks

Jul 16, 2025
pulisher
Jul 15, 2025

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting - The Manila Times

Jul 15, 2025
pulisher
Jul 15, 2025

Apellis Reveals 48-Month SYFOVRE Data: 5 Key Studies Show Promise for Geographic Atrophy Treatment - Stock Titan

Jul 15, 2025
pulisher
Jul 14, 2025

H.C. Wainwright reiterates Buy rating on Apellis Pharmaceuticals stock By Investing.com - Investing.com Canada

Jul 14, 2025
pulisher
Jul 14, 2025

How the (APLS) price action is used to our Advantage - news.stocktradersdaily.com

Jul 14, 2025
pulisher
Jul 11, 2025

Apellis Pharmaceuticals (APLS) Receives a Buy from Cantor Fitzgerald - The Globe and Mail

Jul 11, 2025
pulisher
Jul 11, 2025

Apellis stock holds Outperform rating at William Blair amid Izervay competition - Investing.com Canada

Jul 11, 2025
pulisher
Jul 10, 2025

Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Cantor Fitzgerald reiterates Apellis stock Overweight rating with $39 target By Investing.com - Investing.com Canada

Jul 10, 2025
pulisher
Jul 10, 2025

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Charles River Labs (CRL) - The Globe and Mail

Jul 10, 2025
pulisher
Jul 08, 2025

16 Most Promising Stocks According to Wall Street Analysts - Insider Monkey

Jul 08, 2025
pulisher
Jul 07, 2025

Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating - MSN

Jul 07, 2025
pulisher
Jul 07, 2025

Morgan Stanley raised the Target Price of Apellis Pharmaceuticals (APLS.US) to $26 and maintained a "Hold" rating. - 富途牛牛

Jul 07, 2025
pulisher
Jul 06, 2025

Apellis stock surges after Sobi $300 million royalty deal - MSN

Jul 06, 2025
pulisher
Jul 05, 2025

Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing - MSN

Jul 05, 2025
pulisher
Jul 03, 2025

SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Jul 03, 2025
pulisher
Jul 03, 2025

WilmerHale Advises Apellis Pharmaceuticals in Purchase Agreement with Sobi - WilmerHale

Jul 03, 2025
pulisher
Jul 03, 2025

(APLS) Trading Advice - news.stocktradersdaily.com

Jul 03, 2025
pulisher
Jul 03, 2025

Apellis signs royalty purchase deal with Sobi for Aspaveli - MSN

Jul 03, 2025
pulisher
Jul 03, 2025

Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli - MSN

Jul 03, 2025
pulisher
Jul 03, 2025

Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Apellis Pharmaceuticals (APLS) and Pliant Therapeutics (PLRX) - The Globe and Mail

Jul 03, 2025
pulisher
Jul 02, 2025

What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals - Nasdaq

Jul 02, 2025

Apellis Pharmaceuticals Inc Stock (APLS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):